MMND-ITRO 2025
Sydney
18-22 February

Early Bird Registration ends on 15 January 2025. All other tickets are available until 16 February 2025.

Register now

Registration packages

Additional guest tickets

Laura Dawson, MD, FASTRO

Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada

Laura Dawson is a Professor and Chair of the Department of Radiation Oncology at the University of Toronto, and a practicing radiation oncologist at the Radiation Medicine Program, at Princess Margaret Cancer Centre, in Toronto. She is an internationally recognised leader in hepatobiliary cancer and in oligo-metastases. Her research has primarily focused on the implementation of advanced radiation technologies (e.g. stereotactic body radiation therapy (SBRT) and image-guided radiation therapy (IGRT)) to improve outcomes and reduce the risk of toxicity of cancer patients. She has led phase I, II and more recently, phase III clinical trials of radiation therapy to treat patients with hepatocellular carcinoma and liver metastases. Dr Dawson has published over 200 scientific papers and has mentored over 50 students from around the world. She has received numerous awards for her teaching, research and impact in oncology. She was the 2018 Canadian Association of Radiation Oncology (CARO) Gordon Richards lecturer, and she is the past Chair and past President of the American Society for Radiation Oncology (ASTRO).

Nancy Lee, MD, FASTRO

Memorial Sloan Kettering Cancer Centre, New York, USA

Nancy Y. Lee MD, FASTRO is Vice Chairman of the Department of Radiation Oncology focusing on Experimental Therapeutics. She is also the Proton Service Chief and the Chief of the Head and Neck Radiation Oncology Service at Memorial Sloan Kettering Cancer Center. She is also the Associate Director of the Prevention Interception Program at MSKCC. Dr Lee has appointments in both the Radiation Oncology Department and Early Drug Development Group and is currently the Section Head of the Multimodality Therapeutic Section within Early Drug Development.

Dr Lee was born in Taipei, Taiwan, grew up until age 9 and then immigrated to the USA. She is an internationally renowned academic physician whose research, publications (almost 300 peer-reviewed papers), 3 of the best-selling target delineation books, and lectures have helped radiation oncologists across multiple radiation oncologists harness the powers of IMRT and proton therapy. She has dedicated her career to embracing technology, modernizing clinical practice, and bringing radiation oncology to the forefront of cancer medicine. She is also active in the Society for Immunotherapy of Cancer where she is a co-author of a consensus statement on immunotherapy use for head and neck cancer and has established multiple industry relationships to take command of trials combining novel therapeutic agents with radiation. Dr Lee has served on multiple ASTRO committees and editorial boards. At MSKCC, she has been a tireless advocate for patients and dedicated herself to the education of trainees (receiving multiple ARRO teaching awards and mentoring over 100 radiation oncologists around the world to successful careers of their own in academic and private practices across the country.

Her research focuses on developing novel strategies to personalise cancer treatment with the goal of improving tumor cure and quality of life after radiation treatment for head and neck cancer where she has received several NIH R01 funding, including:

(1) Designing/evaluating novel PET and/or MR imaging metrics to select the best candidates for radiation dose reduction, currently the de-escalation dose is 30Gy with chemotherapy for select locally advanced Human Papilloma Virus (HPV) head and neck squamous cell carcinoma with the ultimate goal of individualizing both radiation and systemic therapy; de-escalation strategies for nasopharyngeal carcinoma, HPV negative tumours; thyroid cancer.

(2) Assessing biologic targeted therapies and using biomarkers such as plasma EBV DNA to individualise treatment for nasopharyngeal, thyroid, and plasma HPV DNA to personalise oropharyngeal cancer; cell free plasma DNA or circulating tumour DNA to direct therapy across different head and neck/thyroid cancer; escalate therapy based on biologic or imaging correlates; and screening for HPV+ oropharyngeal cancer. She is the principal investigator for an international NRG trial personalizing treatment for nasopharyngeal cancer using plasma EBV DNA.

(3) Establishing standard treatment guidelines for therapies such as intensity-modulated radiation therapy (IMRT) and stereotactic body radiotherapy (SBRT), and proton beam for head and neck cancer and focusing efforts on developing FLASH proton therapy with goal of further toxicity reduction.

Her top priority is to help radiation oncology continue to evolve to elevate patient care. She believes this requires actively engaging and providing opportunities for practitioners in all different settings and phases of their careers. Outside of work, Dr Lee is very involved in her church and enjoys travelling with her husband and two boys.

Professor Thomas Rockwell Mackie

University of Wisconsin School of Medicine and Public Health, Wisconsin, USA

Thomas “Rock” Mackie has a Bachelor of Science in Physics (1980) from the University of Saskatchewan and a PhD in Physics (1984) from the University of Alberta. He was a Professor of Medical Physics at the University of Wisconsin from 1987 to 2014 with his last role as Director of Medical Engineering at the Morgridge Institute for Research and since been an emeritus professor.

He has been awarded the Coolidge Gold Medal from the AAPM (2014), the Gold Medal from ASTRO (2019) and the John Mallard Award for Innovation from the IOMP (2019) and is a Fellow of the National Academy of Inventors. He is a commissioner of the International Commission on Radiation Units and Measurements (ICRU) as well as the Vice-Chair of its Board. Rock Mackie has a long entrepreneurial career both as an academic and since retiring as a professor. He is best known for the Pinnacle, a radiation therapy treatment planning system, and TomoTherapy, the first MVCT-guided IMRT company. He is a co-founder of Leo Cancer Care, which is developing upright radiotherapy, OnLume a fluorescent-guided surgery company, and a board member of Shine Medical Technologies which is developing medical isotopes using fusion and fission nuclear reactions.

Yoshiya Yamada, MD, FRCPC

Memorial Sloan Kettering Cancer Centre, New York, USA

Youshiya (Josh) Yamada, MD, FRCPC, is a senior attending radiation oncologist in the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Centre. His clinical and research focus is aspects of stereotactic radiation therapy, particularly in reference to spine tumours. He serves as co-director of the Spine Oncology Service. He has served as invited faculty at many national and international forums, authored nearly 250 peer-reviewed papers, and multiple book chapters, and as senior editor of two textbooks. 

Josh is an avid fly fisherman. He and his wife, Suzy, have five children.

Platinum sponsorship

Sponsors announced shortly 

Gold sponsorship 

Sliver sponsorship 

The conference will be held at the Sheraton Grand Sydney Hyde Park at 161 Elizabeth Street, Sydney, New South Wales, Australia, 2000.

Getting to the Sheraton Grand Sydney Hyde Park

The Sheraton Grand Sydney Hyde Park is situated in the heart of Sydney, Australia. It offers incredible views of downtown Sydney and Hyde Park. It is close to attractions such as St. Mary's Cathedral, Royal Botanic Garden and Middle Harbour. The hotel is well serviced by buses, and trains. Private transfers, rental vehicles, and limousines to and from the airport can be organised. 

Airport Link Trains are available between Sydney Airport and Central Station, approximately every 10 minutes. To use this service, you will need to purchase an Opal Card from the station. 

Nestled in the heart of Sydney, the Sheraton Grand Sydney Hyde Park offers views of downtown Sydney and the lush greenery of Hyde Park. Just a stone’s throw away from iconic attractions such as St. Mary's Cathedral, the Royal Botanic Garden, and Middle Harbour, Sheraton's prime location ensures you’re always close to the action.

The hotel is easily accessible via buses and trains. Private transfers, rental vehicles, and limousines to and from the airport can be easily arranged. 

For a seamless journey, hop on the Airport Link Trains that run every 10 minutes between Sydney Airport and Central Station. Simply purchase an Opal Card from the station, and you’re on your way.

Accommodation

A range of accommodation options are available for the MMND-ITRO 2025 conference to suit all tastes and budgets. Below are some different options: 

• Sheraton Grand Sydney Hyde Park
• Castlereagh Boutique Hotel
• Hilton Sydney
• Meriton Suites
• Pullman Sydney Hyde Park

All visitors to Australia are required to obtain a visa or Electronic Travel Authority (ETA) in advance to be granted entry to Australia.  An ETA provides authorisation to travel to and enter Australia and is electronically linked to your passport.  An ETA is for short term stays for tourism or business visitor activities such as attending a conference/meeting. You can apply for a visa through the Electronic Travel Authority (ETA) online and you’ll be issued a visa instantly if you have a passport from one of the following countries:

• Brunei-Darussalam
• Canada
• Hong Kong (SAR PRC)
• Japan
• Korea, Rep of (South)
• Malaysia
• Singapore
• United States

The Visa application process costs AUD$20.00 using your credit card. Apply here.

PLEASE NOTE: If you are a passport holder of any other country than those listed above, you will need to visit the Department of Home Affairs website  to determine your specific visa entry requirements.  

• You need to select Business activities as this reflects that you are attending a conference. 
• Input your country of passport and age and click next.  You are then directed to which visa is appropriate for you.

Important: The Visa Finder does not provide a complete summary of all the visas that may be available to you and makes no recommendations regarding visas that are appropriate for you; also, it provides no guarantee or assurance that you will be granted a visa, or a particular visa. The Visa Finder is not a substitute for exercising your own judgment, making your own enquiries and/or obtaining independent advice regarding your eligibility for any visa. The Commonwealth of Australia does not guarantee the accuracy, currency or completeness of any material in the Visa Finder. Read to the full disclaimer.

MMND Conference and Welcome Reception

MMND Conference

Special Brachytherapy Day

Gala Dinner

ITRO

ITRO Conference (half day)